InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,738.00
(
0.31%
)
Dow Jones
39,512.84
(
0.00%
)
Brent Oil
83.07
(
0.83%
)
Bitcoin
62,679.51
(
2.00%
)
Post# of 251799
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119621
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 11/24/2014 9:22:28 AM

Monday, November 24, 2014 9:22:28 AM

Post# of 251799
AMGN terminates phase-3 trials of rilotumumab* due to safety problem:

http://finance.yahoo.com/news/amgen-announces-termination-amgen-sponsored-141500865.html

Amgen today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen's decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found an increase in the number of deaths in the rilotumumab and chemotherapy treatment arm when compared to the chemotherapy treatment only arm.

*F/k/a/ AMG 102.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up